Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RLAY, ALKS, TYRA, XENE, SYRE, and represent 32.67% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: ANRO (+$33M), PALI (+$27M), AMLX (+$19M), REPL (+$14M), SYRE (+$13M), ALKS (+$13M), CTNM (+$9.3M), RAPT (+$8.5M), PEPG (+$6.8M), Athira Pharma.
- Started 6 new stock positions in Athira Pharma, RAPT, PALI, REPL, ANRO, CTNM.
- Reduced shares in these 10 stocks: MRUS (-$332M), COGT (-$180M), TERN (-$171M), AGIO (-$94M), NUVL (-$86M), VRDN (-$69M), CDTX (-$56M), PTGX (-$50M), CNTA (-$46M), XENE (-$40M).
- Sold out of its positions in AGIO, APGE, CDTX, ENTA, TNGX, VRDN, VTGN, CBIO, PCSC, MRUS.
- Commodore Capital was a net seller of stock by $-1.1B.
- Commodore Capital has $1.5B in assets under management (AUM), dropping by -26.66%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 33 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Relay Therapeutics (RLAY) | 9.6 | $144M | 17M | 8.46 |
|
|
| Alkermes SHS (ALKS) | 6.6 | $99M | +14% | 3.6M | 27.98 |
|
| Tyra Biosciences (TYRA) | 5.9 | $89M | 3.4M | 26.29 |
|
|
| Xenon Pharmaceuticals (XENE) | 5.4 | $81M | -33% | 1.8M | 44.82 |
|
| Spyre Therapeutics Com New (SYRE) | 5.2 | $78M | +20% | 2.4M | 32.76 |
|
| Cogent Biosciences (COGT) | 5.2 | $78M | -69% | 2.2M | 35.52 |
|
| Enliven Therapeutics (ELVN) | 4.8 | $72M | 4.7M | 15.40 |
|
|
| Celldex Therapeutics Com New (CLDX) | 4.6 | $70M | -15% | 2.6M | 27.16 |
|
| Amylyx Pharmaceuticals (AMLX) | 4.5 | $68M | +38% | 5.7M | 12.08 |
|
| Terns Pharmaceuticals (TERN) | 4.0 | $60M | -74% | 1.5M | 40.40 |
|
| Kymera Therapeutics (KYMR) | 3.9 | $58M | 750k | 77.81 |
|
|
| Soleno Therapeutics (SLNO) | 3.7 | $56M | -11% | 1.2M | 46.30 |
|
| Nuvalent Inc-a (NUVL) | 3.7 | $55M | -60% | 550k | 100.59 |
|
| Oruka Therapeutics (ORKA) | 3.5 | $53M | 1.8M | 30.31 |
|
|
| Pharvaris N V (PHVS) | 3.5 | $52M | -21% | 1.9M | 27.75 |
|
| Nurix Therapeutics (NRIX) | 2.9 | $43M | -39% | 2.3M | 18.97 |
|
| Protagonist Therapeutics (PTGX) | 2.6 | $39M | -56% | 450k | 87.34 |
|
| Assembly Biosciences Com New (ASMB) | 2.3 | $34M | 1.0M | 34.01 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 2.2 | $33M | 1.5M | 22.26 |
|
|
| Cytomx Therapeutics (CTMX) | 2.2 | $33M | 7.7M | 4.26 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 2.2 | $33M | NEW | 1.8M | 17.80 |
|
| Palisade Bio (PALI) | 1.8 | $27M | NEW | 11M | 2.35 |
|
| Mind Medicine Mindmed Com New (MNMD) | 1.8 | $27M | -37% | 2.0M | 13.39 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.7 | $25M | -64% | 1.0M | 25.01 |
|
| Pepgen (PEPG) | 1.5 | $22M | +44% | 3.4M | 6.51 |
|
| Sab Biotherapeutics Com New (SABS) | 1.1 | $17M | 4.4M | 3.74 |
|
|
| Replimune Group (REPL) | 0.9 | $14M | NEW | 1.4M | 9.72 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.7 | $11M | 5.4M | 2.05 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.6 | $9.3M | NEW | 816k | 11.43 |
|
| Avalo Therapeutics Com New (AVTX) | 0.6 | $8.8M | 483k | 18.16 |
|
|
| Rapt Therapeutics Com New (RAPT) | 0.6 | $8.5M | NEW | 250k | 33.87 |
|
| Athira Pharma | 0.2 | $3.5M | NEW | 464k | 7.57 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.1 | $1.5M | -96% | 19k | 78.04 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2025 Q4 filed Feb. 17, 2026
- Commodore Capital 2025 Q3 filed Nov. 14, 2025
- Commodore Capital 2025 Q2 filed Aug. 14, 2025
- Commodore Capital 2025 Q1 filed May 15, 2025
- Commodore Capital 2024 Q4 filed Feb. 14, 2025
- Commodore Capital 2024 Q3 filed Nov. 14, 2024
- Commodore Capital 2024 Q2 filed Aug. 14, 2024
- Commodore Capital 2024 Q1 filed May 15, 2024
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023
- Commodore Capital 2022 Q3 filed Nov. 14, 2022
- Commodore Capital 2022 Q2 filed Aug. 15, 2022